CRISPR Therapeutics AG — Director's Dealing 2021

Sep 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-09-10

Reporting Person: KASINGER JAMES R. (General Counsel and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-10	Common Shares	M	10000	—	Acquired	33911	Direct
2021-09-13	Common Shares	F	4741	$117.86	Disposed	29170	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-10	Restricted Stock Units	$	D	10000	Disposed		Common Shares (10000)	Direct

Footnotes

F1: The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.

F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

F3: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.